Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | ViPOR regimen for R/R B-cell lymphoma

Wyndham Wilson • 2 Jul 2019
ICML 2019
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Ibrutinib Lenalidomide Obinutuzumab Prednisone Venetoclax

The Phase Ib study of venetoclax, ibrutinib, prednisone, obinutuzumab and lenalidomide (ViPOR) for relapsed/refractory B-cell lymphoma was presented at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. Here, Wyndham Wilson, MD, PhD, Center for Cancer Research, National Cancer Institute, Bethesda, MD, explains the safety, efficacy and molecular analysis results.

More from Wyndham Wilson

4:17
Ibrutinib in DLBCL: revelations from further analysis of PHOENIX
Wyndham Wilson • 2 Jul 2019
1:12
Liquid biopsy to measure MRD
Wyndham Wilson • 2 Jul 2019
2:49
Liquid biopsy making strides forward in NHL: detection of ctDNA and mutations
Wyndham Wilson • 2 Jul 2019
23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al. • 9 Apr 2015

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals